Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

NCT02703779 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bortezomib
DRUG: Granulocyte colony-stimulating factor (G-CSF)
DRUG: Mozobil

Sponsor

Siddhartha Ganguly